Michael Gelband’s Crinetics Pharmaceuticals CRNX Stock Holding History

Michael Gelband’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.65M	Buy	+70,882	New	+$2.63M	0.02%	715
2024 Q3	–	Sell	-116,322	Closed	-$5.21M	–	1697
2024 Q2	$5.21M	Buy	116,322 +87,203	+299%	+$4.03M	0.04%	391
2024 Q1	$1.36M	Sell	29,119 -98,563	-77%	-$3.86M	0.01%	844
2023 Q4	$4.54M	Buy	127,682 +98,743	+341%	+$3.03M	0.03%	364
2023 Q3	$861K	Sell	28,939 -163,035	-85%	-$3.36M	0.01%	1014
2023 Q2	$3.46M	Buy	191,974 +44,858	+30%	+$895K	0.03%	585
2023 Q1	$2.36M	Buy	+147,116	New	+$2.72M	0.02%	811

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's CRNX Position: Q2 2026 in Review

Michael Gelband opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 70,882 shares worth $2.65M. The stake represents 0.02% of the portfolio and ranks #715 among its holdings. This is a return to the name: Michael Gelband previously reported a position in CRNX as recently as Q2 2024.

Michael Gelband first reported a position in CRNX in Q1 2023 and has held it in 7 quarters since. The position peaked at $5.21M in Q2 2024. 264 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Michael Gelband held 70,882 shares of Crinetics Pharmaceuticals worth $2.65M as of Q2 2026.
Crinetics Pharmaceuticals was a new Michael Gelband position in Q2 2026.
Crinetics Pharmaceuticals made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #715 holding.
Michael Gelband first reported a position in Crinetics Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
Michael Gelband's Crinetics Pharmaceuticals position peaked at $5.21M in Q2 2024.
264 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.